Please read Dr. Singla’s article in PLOS ONE titled, “A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection.“
A novel coronavirus was first reported in December 2019 and declared an international pandemic by the World Health Organization (WHO) on March 11, 2020. Approximately, 18–19 months later, more than 250 million cases have been confirmed resulting in over 5 million deaths. A number of new therapeutic strategies have been examined globally to attempt to mitigate disease severity and overall mortality related to this virus, yet there remains limited FDA authorized medications to treat coronavirus disease 2019 (COVID-19) patients with generally equivocal results, such as Remdesivir, Baricitinib, Molnupiravir, and Paxlovid. Thus, further development of effective preventative and therapeutic interventions to combat this disease is paramount as we continue to move forward in the ongoing pandemic and as new variant strains are identified. To read the full article.
A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection. Singla A, Dadario NB, Singla A, Greenberg P, Yan R, Nanda A, Boison D, Malhotra R, Patel S, Nipun S, Maninderpal K, Castro D, Bdiiwi S, Boktor H, Kyi HH, Sutherland A, Patrawalla A, Ly K, Xie Y, Sonig A, Khandelwal P, Liu J, Koziol J, Finkle D, Subanna S, Libutti SK. PLoS One. 2023 Jan 30;18(1):e0274243. PMID: 36716303 PMCID: PMC9886260 DOI: 10.1371/journal.pone.0274243